Taberdine L






Names

    • Taberdine L

Attributes

  • Canonical SMILES

    [H][C@@]12C3=C(CC[N+](C4)([O-])[C@]1([H])C[C@@H](O)[C@@]4(CC)C2)C5=CC=CC=C5N3

  • InChI

    InChI=1S/C19H24N2O2/c1-2-19-10-14-16(9-17(19)22)21(23,11-19)8-7-13-12-5-3-4-6-15(12)20-18(13)14/h3-6,14,16-17,20,22H,2,7-11H2,1H3/t14-,16+,17+,19-,21?/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 59.08
  • #RotBonds: 1
  • MW: 312.41299999999995
  • HBD: 2
  • HBA: 2
  • logP: 3.055500000000001
  • Chemical Formula: C19H24N2O2


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. divaricata China, Japan, Thailand, Bangladesh, Vienna 52861 BBP0671

External Databases


References

  • Taberdines L and M, two new alkaloids from Tabernaemontana divaricata. Nat Prod Res, 2022 (PMID 34933610).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.63
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.89
    Human Oral Bioavailability 50% Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -1.92
    Distribution Blood-Brain Barrier (Central Nervous System) -3.52
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.48
    Plasma Protein Binding 75.79
    Steady State Volume of Distribution 1.24
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 13.35
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.57
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.6
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 4.75
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis 1.53
    Rat (Acute) 2.88
    Rat (Chronic Oral) 2.08
    Fathead Minnow 3.92
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 435.29
    Hydration Free Energy -7.03
    Log(D) at pH=7.4 1.85
    Log(P) 1.4
    Log S -1.49
    Log(Vapor Pressure) -10.51
    Melting Point 275.31
    pKa Acid 7.19
    pKa Basic 3.75